Atlas Trials

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

Clinical trial NCT04601857 · TERMINATED

Trial details

NCT number
NCT04601857
Sponsor
Taiho Oncology, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced and Metastatic Urothelial Cancer
Start date
2021-01-07
Primary completion
2024-03-08
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.